

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
March 21, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Enanta Pharmaceuticals, Inc.

File No. 333-184779 - CF#28829

Enanta Pharmaceuticals, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on November 6, 2012, as amended.

Based on representations by Enanta Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

| | |
|--------------|--------------------------|
| Exhibit 10.1 | through February 5, 2016 |
| Exhibit 10.2 | through February 5, 2016 |
| Exhibit 10.3 | through March 30, 2014 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Jennifer Riegel
Special Counsel